Edmond DE Rothschild Holding S.A. Purchases Shares of 687,030 BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Edmond DE Rothschild Holding S.A. purchased 687,030 BioMarin shares worth approximately $39.3 million, representing about 0.35% of the company. Institutional investors and hedge funds collectively own 98.71% of BMRN.
• BioMarin reported quarterly earnings of $1.20 per share, beating estimates of $0.95, while revenue rose 20% year over year to $989.7 million. The stock recently traded at $69.33, near its 52-week high.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $88.83; however, some analysts have maintained neutral ratings or lowered targets, reflecting valuation and execution risks.

Edmond DE Rothschild Holding S.A. purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 687,030 shares of the biotechnology company's stock, valued at approximately $39,312,000. Edmond DE Rothschild Holding S.A. owned approximately 0.35% of BioMarin Pharmaceutical at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BMRN. Activest Wealth Management acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $26,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in BioMarin Pharmaceutical during the second quarter valued at approximately $39,000. CIBC Private Wealth Group LLC boosted its position in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in BioMarin Pharmaceutical in the third quarter valued at approximately $40,000. Finally, Parallel Advisors LLC grew its stake in BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 295 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $69.33 on Thursday. The stock has a 50 day simple moving average of $60.21 and a 200 day simple moving average of $57.74. The stock has a market cap of $13.42 billion, a P/E ratio of 187.38, a PEG ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a 1-year low of $49.26 and a 1-year high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company's revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.11 earnings per share for the current year.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The transaction gives BioMarin rights to ALE1, an oral therapy being developed for hypophosphatasia (HPP), a rare genetic bone disorder. The potential to offer a first oral treatment could address a significant unmet need and expand BioMarin’s presence in rare skeletal diseases. CNBC article
• Positive Sentiment: Investors and analysts see strategic and longer-term growth potential from adding ALE1 to BioMarin’s pipeline. Wedbush said the acquisition strengthens the company’s outlook, while BMO Capital Markets initiated coverage with an Outperform rating and a $98 price target, implying substantial upside from the referenced price. Barclays and Piper Sandler also issued bullish forecasts. Wedbush article
• Neutral Sentiment: The acquisition broadens BioMarin’s rare-disease portfolio, but ALE1 is still in early clinical trials. Its commercial value depends on successful development, regulatory approval and achievement of milestones, making the program a longer-term rather than immediate revenue driver. Alesta will also spin out its other assets before closing. BioMarin announcement
• Negative Sentiment: HC Wainwright lowered its price target from $60 to $59 and maintained a Neutral rating, while another analyst cut its target to $59. These targets suggest some investors believe the stock’s recent rise has outpaced near-term fundamentals and that execution and valuation risks remain. Analyst coverage

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BMRN shares. Bank of America lowered their price target on BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating on the stock in a research report on Tuesday, May 19th. UBS Group reissued a "neutral" rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Piper Sandler boosted their target price on shares of BioMarin Pharmaceutical from $82.00 to $88.00 and gave the stock an "overweight" rating in a report on Monday. Canaccord Genuity Group upped their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Finally, The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research note on Monday, May 11th. They issued a "neutral" rating and a $69.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $88.83.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source